Solvonis Engages PharmaVentures for AUD Treatment Commercialisation

Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an announcement.

Solvonis Therapeutics plc has engaged PharmaVentures to assist in the commercialisation of two clinical-stage programmes, AWKN-001 and AWKN-002, aimed at treating Alcohol Use Disorder (AUD). This collaboration follows Solvonis’ proposed acquisition of Awakn Life Sciences Corp. The engagement is structured in two phases, with the first phase involving a market analysis that has already been completed. The analysis highlights the significant commercial potential of these programmes, with a potential combined value exceeding £200 million. This strategic move is expected to enhance Solvonis’ market positioning and create substantial value for shareholders.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders. The company co-develops therapeutics for mental health disorders, with an initial focus on trauma-related mental health conditions such as PTSD, which affects millions across the U.S., UK, and EU markets.

YTD Price Performance: -21.50%

Average Trading Volume: 12,169,357

Technical Sentiment Signal: Strong Buy

Current Market Cap: £3.62M

For an in-depth examination of SVNS stock, go to TipRanks’ Stock Analysis page.